US 12,313,638 B2
Method for analyzing blood coagulation characteristics of blood specimen
Toshiki Kawabe, Chuo-ku (JP); Yukio Oda, Chuo-ku (JP); Midori Shima, Kashihara (JP); Keiji Nogami, Kashihara (JP); and Kenichi Ogiwara, Kashihara (JP)
Assigned to SEKISUI MEDICAL CO., LTD., Chuo-ku (JP); and PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, Kashihara (JP)
Appl. No. 17/427,000
Filed by SEKISUI MEDICAL CO., LTD., Chuo-ku (JP); and PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, Kashihara (JP)
PCT Filed Jan. 31, 2020, PCT No. PCT/JP2020/003796
§ 371(c)(1), (2) Date Jul. 29, 2021,
PCT Pub. No. WO2020/158948, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 2019-016474 (JP), filed on Jan. 31, 2019.
Prior Publication US 2022/0146537 A1, May 12, 2022
Int. Cl. G01N 33/86 (2006.01); G01N 21/47 (2006.01)
CPC G01N 33/86 (2013.01) [G01N 21/47 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method for analyzing a blood specimen, comprising:
acquiring a waveform related to a coagulation rate or a coagulation acceleration of a sample obtained by mixing a subject blood specimen with a reagent for measuring a coagulation time;
extracting a plurality of parameters characterizing the waveform related to the coagulation rate or the coagulation acceleration, the plurality of parameters including a plurality of coagulation rate parameters characterizing a plurality of calculation target areas of the waveform related to the coagulation rate, a plurality of coagulation acceleration parameters characterizing a plurality of calculation target areas of the waveform related to the coagulation acceleration, or a combination of the plurality of coagulation rate parameters and the plurality of coagulation acceleration parameters;
determining an activity level or activity abnormality of a coagulation factor in the subject blood specimen on the basis of the plurality of parameters; and
applying a treatment to a patient according to the activity level or activity abnormality of the coagulation factor, wherein
the plurality of parameters comprise one or more selected from the group consisting of:
a weighted average time vT, a weighted average height vH, a peak width vB, and a weighted average peak width vW, a B flattening vAB for the weighted average height, a W flattening vAW for the weighted average height, a B time rate vTB for the weighted average time, a W time rate vTW for the weighted average time, an average time vTa, an average height vHa, a B flattening vABa for the average height, a W flattening vAWa for the average height, an area start point time vTs, an area end point time vTe, an area median time vTm, an area time width vTr, a main peak start point time vNs, a main peak end point time vNe, and a main peak width vN for the plurality of calculation target areas of the waveform related to the coagulation rate;
a weighted average time pT, a weighted average height pH, a peak width pB, and a weighted average peak width pW, a B flattening pAB for the weighted average height, a W flattening pAW for the weighted average height, a B time rate pTB for the weighted average time, a W time rate pTW for the weighted average time, a main peak start point time pNs, a main peak end point time pNe, and a main peak width pN for a plurality of calculation target areas of a plus peak of the waveform related to the coagulation acceleration; and
a weighted average time mT, a weighted average height mH, a peak width mB, and a weighted average peak width mW, a B flattening mAB for the weighted average height, a W flattening mAW for the weighted average height, a B time rate mTB for the weighted average time, a W time rate mTW for the weighted average time, a main peak start point time mNs, a main peak end point time mNe, and a main peak width mN for a plurality of calculation target areas of a minus peak of the waveform related to the coagulation acceleration.